by Noah Blaine

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have…

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma

source https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-105900675.html?.tsrc=rss

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.